Cancer therapy is 2013 breakthrough: Science journal

December 19, 2013 by Kerry Sheridan

A way of fighting cancer that turns the body's immune cells into targeted tumor killers was named the breakthrough of the year by the US journal Science on Thursday.

Immunotherapy has only worked for a small number of patients, and only in certain cancers, including and leukemia, but experts believe its promise is huge.

"Oncologists, a grounded-in-reality bunch, say a corner has been turned and we won't be going back," said the journal Science.

Research began in the late 1980s when French scientists discovered a receptor on T-cells, called CTLA-4, a molecule that turned out to play an important role in regulating the immune system.

A decade later, a Texas researcher showed that blocking CTLA-4 in mice "could unleash T-cells against tumor cells in the animals, shrinking them dramatically," the journal said.

More advances have followed. In the 1990s, a biologist in Japan discovered a molecule expressed in dying T-cells, called PD-1, which has also shown promise in the fight against .

As many as five big pharmaceutical companies are now on board with immunotherapy. A new drug made by Bristol Myers-Squibb was approved in 2011. Called ipilimumab, it costs $120,000 per treatment course.

It's costly, and by no means a sure bet. Research in 2012 on a group of 300 people showed the drug shrunk tumors by half or more in 31 percent of patients with melanoma, 29 percent with and 17 percent with .

Research out this year on 1,800 people with melanoma who received ipilimumab, 22 percent were alive three years later.

A related treatment called chimeric antigen receptor therapy, which involves modifying a patient's own T-cells to make them attack tumors, has succeeded in putting 45 of 75 people with leukemia in total remission, researchers said this year.

One of those success stories is Emily Whitehead, now age eight. Last year she became the first pediatric patient to receive the experimental therapy for (ALL).

"She is doing great. She is almost 20 months cancer free now. Her health has just been wonderful. She is completely back to normal, back to school full time," her mother, Kari, told AFP.

Emily was at the brink of death, and after two relapses doctors admitted they had no options. Their hope was suddenly revived when her family learned about the experimental T-cell therapy and agreed to try it.

"There just wasn't anything left for her," her mother said. "This treatment has just been amazing for Emily and for all the other families who were told the same thing."

The journal Science and its publisher, the American Association for the Advancement of Science, pointed to other key achievements in its annual top 10 breakthroughs issue.

They included:

- A new generation of cheaper solar cells called Perovskite cells, which are gaining efficiency and are cheaper than traditional silicon cells.

- Progress in growing lab versions of miniature human organs such as brains, kidneys and liver buds to better understand human disease.

- Stem cells derived from cloned human embryos.

- A better understanding of how sleep allows the brain to clean itself by expanding channels between neurons and allowing more cerebrospinal fluid to flow through.

- The importance of microbes in the understanding of the body's overall health.

- A new way of designing a vaccine using the structure of an antibody, cheered for its potential against a common childhood illness, respiratory syncytial virus.

- The origin of cosmic rays was figured out after 100 years. It turns out they come from debris clouds left by supernovae, or exploding stars.

The journal Nature also released its list of the top scientists of 2013.

They included Russian meteorite hunter Viktor Grokhovsky, whose 30 years of expertise helped advance the study of a massive Chelyabinsk meteor that took astronomers by surprise when it crashed to Earth in February.

Another was Chinese virologist Hualan Chen, who helped quell an outbreak of H7N9 bird flu in humans by rushing to collect samples, leading to the closure of risky poultry markets. She also published controversial research on engineered H1N1 and H5N1 flu hybrids that could pass between mammals.

Explore further: T cell immunotherapy: Promising results in children and adults with leukemia

Related Stories

T cell immunotherapy: Promising results in children and adults with leukemia

December 7, 2013
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune ...

Clinical trial examines use of human immune system to fight aggressive lung cancer

December 19, 2013
Researchers at the Cincinnati Cancer Center (CCC) and the UC Cancer Institute are conducting a clinical trial examining a method to stimulate the human immune system to destroy or block the growth of lung cancer cells.

Melanoma drug holding up well after further testing

July 12, 2013
Merck's late-stage melanoma drug, lambrolizumab, continues to show great promise in shrinking the deadly tumors, particularly when taken at the highest dosage offered in trials, according to a study published Thursday in ...

Finding antitumor T cells in a patient's own cancer

November 13, 2013
Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer ...

Experimental drug shows encouraging results in treating most common form of lung cancer

November 1, 2013
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among ...

Killer cocktail fights brain cancer

November 25, 2013
A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.